Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT06419634)
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Interventional
Phase 1
Northwestern Memorial Hospital
Sponsor: Bristol Myers Squibb
Last Updated: October 30, 2025 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Treatment Category
Other Drugs, Targeted Therapy
Required Mutations
None
Trial Started
May 29, 2024
Last Updated by Sponsor
October 30, 2025
Estimated Completion
February 1, 2027
Contact Study
Name:BMS Study Connect Contact Center www.BMSStudyConnect.com